Abstract
Idiopathic rapid eye movement (REM) sleep behavioural disorder (RBD) is classified as one of the REM parasomnias with clinical characteristics including unpleasant dreams, acting out of dreams, and loss of the typical muscle atonia during the REM phase of sleep. Other associated clinical features include olfactory loss, dysautonomia, colour vision impairment and subtle Parkinsonian signs. RBD has been shown to predict development of an alpha-synucleinopathy in 20–45 % of patients within 5 years, and up to 92 % within 14 years post-diagnosis. Hence, this disorder provides a potential opportunity for understanding the prodromal stages of the synucleinopathies and exploring efficacy of potential neuroprotective agents.
Highlights
Idiopathic rapid eye movement (REM) sleep behavioural disorder (RBD) is classified as one of the REM parasomnias with clinical characteristics including unpleasant dreams, acting out of dreams, and loss of the typical muscle atonia during the REM phase of sleep
RBD has been shown to predict development of an alphasynucleinopathy in 20–45 % of patients within 5 years, and up to 92 % within 14 years post-diagnosis. This disorder provides a potential opportunity for understanding the prodromal stages of the synucleinopathies and exploring efficacy of potential neuroprotective agents
RBD patients demonstrated a similar performance to the GBA mutation-negative Parkinson’s disease (PD) cohort with a significantly lower overall performance (p = 0.025 and p = 0.003, respectively) and, a higher proportion of random responses (p = 0.001 and p = 0.024) compared to controls
Summary
Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders Idiopathic rapid eye movement (REM) sleep behavioural disorder (RBD) is classified as one of the REM parasomnias with clinical characteristics including unpleasant dreams, acting out of dreams, and loss of the typical muscle atonia during the REM phase of sleep.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have